Please login to the form below

Not currently logged in
Email:
Password:

SMC

This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

Latest news

More from news
Approximately 15 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year.

  • The Orkambi row explained The Orkambi row explained

    December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system.

  • The Orkambi blame game The Orkambi blame game

    Leiden also claimed the breakthrough in Scotland came when NICE’s equivalent, the SMC, agreed to ‘flex’ its methodology – something which he and other industry leaders said is vital if NICE

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • YorkTown

    decision makers associated with pharmaceutical and medical device/diagnostics market access and HEOR; Developing and writing single technology appraisals (STA) (pharmaceutical and medical device) for regulatory institutions (NICE, EMA, SMC and

  • The Holistic Approach to Market Access

    and to provide local prescribing audit data for inclusion into NICE and SMC technical appraisals the gaining of which is a key element in gaining regional prescribing uptake.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics